Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

575 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aliskiren attenuates oxidative stress and improves tubular status in non-diabetic patients with chronic kidney disease-Placebo controlled, randomized, cross-over study.
Renke M, Lizakowski S, Tylicki L, Rutkowski P, Knap N, Heleniak Z, Sławińska-Morawska M, Aleksandrowicz-Wrona E, Januszczyk J, Wójcik-Stasiak M, Małgorzewicz S, Woźniak M, Rutkowski B. Renke M, et al. Among authors: rutkowski b, rutkowski p. Adv Med Sci. 2014 Sep;59(2):256-60. doi: 10.1016/j.advms.2014.03.003. Epub 2014 Jun 10. Adv Med Sci. 2014. PMID: 25105662 Clinical Trial.
The effect of N-acetylcysteine on proteinuria and markers of tubular injury in non-diabetic patients with chronic kidney disease. A placebo-controlled, randomized, open, cross-over study.
Renke M, Tylicki L, Rutkowski P, Larczyński W, Aleksandrowicz E, Lysiak-Szydłowska W, Rutkowski B. Renke M, et al. Among authors: rutkowski b, rutkowski p. Kidney Blood Press Res. 2008;31(6):404-10. doi: 10.1159/000185828. Epub 2008 Dec 18. Kidney Blood Press Res. 2008. PMID: 19092257 Clinical Trial.
Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
Renke M, Tylicki L, Rutkowski P, Knap N, Zietkiewicz M, Neuwelt A, Aleksandrowicz E, Łysiak-Szydłowska W, Woźniak M, Rutkowski B. Renke M, et al. Among authors: rutkowski b, rutkowski p. Acta Biochim Pol. 2010;57(1):119-23. Epub 2010 Mar 22. Acta Biochim Pol. 2010. PMID: 20309434 Clinical Trial.
The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?
Tylicki L, Lizakowski S, Rutkowski P, Renke M, Sulikowska B, Heleniak Z, Donderski R, Bednarski R, Przybylska M, Manitius J, Rutkowski B. Tylicki L, et al. Among authors: rutkowski b, rutkowski p. Kidney Blood Press Res. 2012;36(1):335-43. doi: 10.1159/000343391. Epub 2012 Dec 12. Kidney Blood Press Res. 2012. PMID: 23235363 Free article. Clinical Trial.
Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial.
Lizakowski S, Tylicki L, Renke M, Rutkowski P, Heleniak Z, Sławińska-Morawska M, Aleksandrowicz E, Łysiak-Szydłowska W, Rutkowski B. Lizakowski S, et al. Among authors: rutkowski b, rutkowski p. Int Urol Nephrol. 2012 Dec;44(6):1763-70. doi: 10.1007/s11255-011-0110-z. Int Urol Nephrol. 2012. PMID: 23326865 Free PMC article. Clinical Trial.
575 results